B+
Bull case
25%
Probability
Target price
$0.53
-95.0% vs current
DCTH
DelcathDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
40%
Probability
Target price
$0.30
-97.2% vs current
B-
Bear case
35%
Probability
Target price
$0.15
-98.6% vs current
AI sentiment snapshot
Latest data as of 2025-09-28
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-negative: investors emphasize financing and commercialization risk for this microcap while a minority cite binary regulatory or adoption catalysts as re-rating opportunities [#10Qp5], [#PR-2024-07]. Trading volume is thin and news-driven moves have dominated price action recently [#MarketData-2025-09].
RankAlpha Sentiment AI - 2025-09-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventPotential regulatory developments for chemosaturation systemHigh impact
Any FDA communications, label changes, or new PMA/510(k) activity related to Delcath's chemosaturation / melphalan delivery system could materially move the stock; regulatory timing is uncertain [#10Qp12].
-catalystCommercial adoption / new reimbursementHigh impact
Improved commercial uptake or new reimbursement for targeted liver infusion therapy would support longer-term valuation upside; adoption timelines typically multi-quarter [#PR-2024-07].
2025-12-31catalystLiquidity / financing dilutionHigh impact
Small-cap cash needs may force equity raises that dilute shareholders and depress near-term price; financing risk is high for sub-$1 stocks [#10Qp5].
Recommendation
N/A
No formal recommendation provided.
As of 2025-09-28 • Updated nightlySource: Internal modelMethodology